ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.

S. Florman,1 J. Medina Pestana,2 M. del C Rial,3 L. Rostaing,4 D. Kuypers,5 A. Matas,6 T. Wekerle,7 J. Grinyó,8 U. Meier-Kriesche,9 M. Polinsky,9 H. Zhao,9 A. Durrbach.10

1Mount Sinai Med Ctr, New York
2Hosp do Rim, Sao Paulo, Brazil
3Instituto de Nefrologia, Buenos Aires, Argentina
4Univ Hosp, Toulouse, France
5Univ Hosp Leuven, Leuven, Belgium
6Univ of Minnesota, Minneaopolis
7Med Univ of Vienna, Vienna, Austria
8Univ Hosp Bellvitge, Barcelona, Spain
9BMS, Lawrenceville
10Univ Hôpital of Bicêtre, Le Kremlin-Bicêtre, France.

Meeting: 2016 American Transplant Congress

Abstract number: D138

Keywords: Cadaveric organs, Epstein-Barr virus (EBV), Kidney transplantation

Session Information

Date: Tuesday, June 14, 2016

Session Name: Poster Session D: Kidney Immunosuppression: Novel Agents

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.
  • Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT.

At 7 yrs post transplant in BENEFIT-EXT (NCT00114777), bela-treated pts had similar graft survival and improved renal function vs CsA-treated pts. Bela is indicated for use only in EBV-positive pts. Outcomes in BENEFIT-EXT pts who were EBV-positive prior to transplant are described.

Recipients of extended criteria donor kidneys were randomized to receive bela more intense (MI), bela less intense (LI), or CsA immunosuppression. All randomized, transplanted EBV-positive pts were analyzed through 7 yrs post-transplant. Time to death or graft loss was compared between regimens using Cox regression. GFR was estimated from months 1–84 using a repeated measures model.

Of 543 randomized pts, 496 were EBV-positive. Of these, 121/170 bela MI-treated, 124/157bela LI-treated, and 102/169 CsA-treated pts were evaluable for death/graft loss at 7 yrs. Hazard ratios comparing time to death/graft loss were 0.784 for bela MI vs CsA (P=.40) and 0.819 for bela LI vs CsA (P=.48) (Fig.). Serious AE rates were similar (87%, bela MI; 89%, bela LI; 84%, CsA). Estimated mean GFR increased over 7 yrs for both bela regimens but declined for CsA (estimated mean GFR at yr 7: bela MI, 53.5; bela LI, 53.6; CsA, 36.1 mL/min/1.73 m2). GFR slopes diverged between bela and CsA over time; the interaction of the treatment vs time effect deriving from the model favored each bela regimen vs CsA (P≤.001). Among bela-treated pts, PTLD occurred in 3 EBV-positive and 5 EBV-negative pts by month 84.

Outcomes in the subset of EBV-positive pts were consistent with those observed in the ITT population: bela was associated with similar death/graft loss and improved renal function vs CsA.

CITATION INFORMATION: Florman S, Medina Pestana J, del C Rial M, Rostaing L, Kuypers D, Matas A, Wekerle T, Grinyó J, Meier-Kriesche U, Polinsky M, Zhao H, Durrbach A. Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Florman S, Pestana JMedina, Rial MdelC, Rostaing L, Kuypers D, Matas A, Wekerle T, Grinyó J, Meier-Kriesche U, Polinsky M, Zhao H, Durrbach A. Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-outcomes-in-epstein-barr-virus-ebv-positive-patients-receiving-belatacept-bela-or-cyclosporine-csa-in-benefit-ext/. Accessed March 6, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Role of Mitochondria, Metabolism and Inflammation: Pathways Influencing Short Term Outcomes Post-Renal Transplantation
    • Factors Influencing Creatinine Rise Following Donor Nephrectomy

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.